Home LiteratureArticle Details
PMID: 11753652 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain.

Oncogene ·Vol. 20 ·No. 53 ·2001-11-22 ·Pages 7744-52

Brasher BB, Roumiantsev S, Van Etten RA

Abstract

The catalytic activity of the c-Abl tyrosine kinase is tightly regulated by its Src homology 3 (SH3) domain through a complex mechanism that may involve intramolecular binding to Pro242 in the linker region between the SH2 and catalytic domains as well as interactions with a trans-inhibitor. We analysed the effect of mutation or replacement of SH3 on c-Abl tyrosine kinase activity and transformation. Random mutagenesis of SH3 identified several novel point mutations that dysregulated c-Abl kinase activity in vivo, but the RT loop was insensitive to mutational activation. Activating SH3 mutations abolished binding of proline-rich SH3 ligands in vitro, while mutations at Ser140 in the connector between the SH3 and SH2 domains activated Abl kinase activity in vivo and in vitro but did not impair SH3 ligand-binding. Abl was regulated efficiently when its SH3 domain was replaced with a heterologous SH3 from c-Src that binds a different spectrum of proline-rich ligands, but not by substitution of a modular WW domain with similar ligand-binding specificity. These results suggest that the SH3 domain regulates Abl principally by binding to the atypical intramolecular ligand Pro242 rather than a canonical PxxP ligand. Coordination between the SH3 and SH2 domains mediated by the connector region may be required for regulation of Abl even in the absence of SH2 ligand binding.

MeSH Terms
Amino Acid Sequence Animals Blotting, Far-Western Caenorhabditis elegans Catalysis Cell Line Cell Transformation, Neoplastic Enzyme Activation Kinetics Ligands Mutagenesis/genetics Point Mutation/genetics Protein Binding Protein Structure, Tertiary/genetics Proto-Oncogene Proteins c-abl/chemistry,genetics,metabolism Recombinant Fusion Proteins/chemistry,genetics,metabolism Reverse Transcriptase Polymerase Chain Reaction Sequence Homology, Amino Acid Substrate Specificity src Homology Domains/genetics
Chemicals
Ligands Recombinant Fusion Proteins Proto-Oncogene Proteins c-abl
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Brasher B B
Enanta Pharmaceuticals, 500 Arsenal Street, Watertown, MA 02472, USA.
Roumiantsev S
Van Etten R A
Article Info
Journal
Oncogene
Abbr.
Oncogene
ISSN
0950-9232
Published
2001-11-22
Pages
7744-52
Language
English
Region
England
NLM ID
8711562
Subset
IM
Grants
NCI NIH HHS · CA72465 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]